CompletedPhase 2NCT02734862
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
Studying Rare mycosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cidara Therapeutics Inc.
- Principal Investigator
- Taylor Sandison, MD MPHCidara Therapeutics
- Intervention
- CD101(drug)
- Enrollment
- 207 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2019
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of California - Davis, Davis, California, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Augusta University, Augusta, Georgia, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Harper University Hospital, Detroit, Michigan, United States
- Henry Ford Health System, Detroit, Michigan, United States
- William Beaumont Hospital, Royal Oak, Michigan, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Mercury Street Medical, Butte, Montana, United States
- Albany Medical Center, Albany, New York, United States
- Mercy Health - St. Vincent Medical Center - ID Clinical Research, Toledo, Ohio, United States
- Reading Hospital and Medical Center, West Reading, Pennsylvania, United States
- University of Texas Health Science Center at Houston, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02734862 on ClinicalTrials.gov